ARTICLE | Company News
iDD Biotech, Genmab deal
April 20, 2015 7:00 AM UTC
Genmab purchased from iDD preclinical antibodies targeting tumor necrosis factor (TNF) receptor superfamily member 10b ( TNFRSF10B; DR5; TRAILR2; CD262) and related patents. Genmab said TRAILR2 is ...